Citigroup
SGMO

Citigroup’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Citigroup’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,369
Closed -$922 – 6423
2025
Q3 		$922 Sell
1,369
-90
-6% -$49 ﹤0.01% 5635
2025
Q2 		$790 Sell
1,459
-92,420
-98% -$54.9K ﹤0.01% 5419
2025
Q1 		$61.6K Sell
93,879
-61,007
-39% -$64.6K ﹤0.01% 4821
2024
Q4 		$158K Buy
154,886
+151,647
+4,682% +$277K ﹤0.01% 4563
2024
Q3 		$2.81K Sell
3,239
-21,421
-87% -$15.7K ﹤0.01% 5388
2024
Q2 		$8.84K Sell
24,660
-6,980
-22% -$3.77K ﹤0.01% 5171
2024
Q1 		$21.2K Buy
31,640
+3,119
+11% +$2.26K ﹤0.01% 5015
2023
Q4 		$15.5K Buy
28,521
+26,007
+1,034% +$12K ﹤0.01% 5075
2023
Q3 		$1.51K Sell
2,514
-43,474
-95% -$46.5K ﹤0.01% 5026
2023
Q2 		$59.8K Sell
45,988
-568,405
-93% -$777K ﹤0.01% 4535
2023
Q1 		$1.08M Buy
614,393
+274,818
+81% +$784K ﹤0.01% 2479
2022
Q4 		$1.07M Sell
339,575
-57,763
-15% -$224K ﹤0.01% 2558
2022
Q3 		$1.95M Buy
397,338
+50,655
+15% +$260K ﹤0.01% 2161
2022
Q2 		$1.44M Buy
346,683
+221,118
+176% +$956K ﹤0.01% 2359
2022
Q1 		$730K Sell
125,565
-238,505
-66% -$1.42M ﹤0.01% 3223
2021
Q4 		$2.73M Buy
364,070
+133,357
+58% +$1.16M ﹤0.01% 2354
2021
Q3 		$2.08M Sell
230,713
-217,439
-49% -$2.15M ﹤0.01% 2515
2021
Q2 		$5.37M Buy
448,152
+11,878
+3% +$134K ﹤0.01% 1840
2021
Q1 		$5.47M Buy
436,274
+292,577
+204% +$3.94M ﹤0.01% 1724
2020
Q4 		$2.24M Sell
143,697
-1,975
-1% -$23.1K ﹤0.01% 2742
2020
Q3 		$1.38M Sell
145,672
-110,173
-43% -$1.19M ﹤0.01% 2982
2020
Q2 		$2.29M Buy
255,845
+16,866
+7% +$156K ﹤0.01% 2667
2020
Q1 		$1.52M Buy
238,979
+80,981
+51% +$601K ﹤0.01% 2760
2019
Q4 		$1.32M Sell
157,998
-84,928
-35% -$781K ﹤0.01% 3455
2019
Q3 		$2.2M Buy
242,926
+100,633
+71% +$1.13M ﹤0.01% 2758
2019
Q2 		$1.53M Buy
142,293
+49,864
+54% +$530K ﹤0.01% 3148
2019
Q1 		$882K Sell
92,429
-338,175
-79% -$3.45M ﹤0.01% 3547
2018
Q4 		$4.94M Buy
430,604
+328,137
+320% +$4.08M 0.01% 1823
2018
Q3 		$1.74M Sell
102,467
-79,233
-44% -$1.2M ﹤0.01% 2893
2018
Q2 		$2.58M Buy
181,700
+57,842
+47% +$961K ﹤0.01% 2460
2018
Q1 		$2.35M Sell
123,858
-34,739
-22% -$743K ﹤0.01% 2461
2017
Q4 		$2.6M Buy
158,597
+99,161
+167% +$1.48M ﹤0.01% 2426
2017
Q3 		$891K Buy
59,436
+48,852
+462% +$540K ﹤0.01% 3503
2017
Q2 		$93K Buy
10,584
+3,917
+59% +$25.1K ﹤0.01% 5414
2017
Q1 		$35K Sell
6,667
-21,900
-77% -$87.8K ﹤0.01% 5936
2016
Q4 		$87K Buy
28,567
+13,724
+92% +$50K ﹤0.01% 5856
2016
Q3 		$69K Buy
14,843
+3,930
+36% +$20K ﹤0.01% 5446
2016
Q2 		$62K Sell
10,913
-43,251
-80% -$276K ﹤0.01% 5424
2016
Q1 		$327K Buy
54,164
+37,778
+231% +$227K ﹤0.01% 4607
2015
Q4 		$149K Sell
16,386
-63,498
-79% -$489K ﹤0.01% 5020
2015
Q3 		$450K Buy
79,884
+57,098
+251% +$471K ﹤0.01% 3839
2015
Q2 		$253K Sell
22,786
-5,203
-19% -$67.1K ﹤0.01% 4250
2015
Q1 		$439K Sell
27,989
-13,879
-33% -$215K ﹤0.01% 3869
2014
Q4 		$638K Buy
41,868
+23,220
+125% +$282K ﹤0.01% 3621
2014
Q3 		$201K Buy
18,648
+6,042
+48% +$78.9K ﹤0.01% 4238
2014
Q2 		$192K Sell
12,606
-5,884
-32% -$84.6K ﹤0.01% 4163
2014
Q1 		$334K Sell
18,490
-18,591
-50% -$358K ﹤0.01% 3856
2013
Q4 		$516K Buy
37,081
+22,156
+148% +$255K ﹤0.01% 3768
2013
Q3 		$156K Buy
14,925
+10,880
+269% +$108K ﹤0.01% 4377
2013
Q2 		$32K Buy
+4,045
New +$35.3K ﹤0.01% 5613

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Citigroup's SGMO Position: Q4 2025 in Review

Citigroup sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 1,369 shares — an estimated $922 sold.

Citigroup first reported a position in SGMO in Q2 2013 and held it in 50 quarters. The position peaked at $5.47M in Q1 2021. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • Citigroup reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 1,369 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $922.
  • Citigroup first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 50 quarters.
  • Citigroup's SANGAMO THERAPEUTICS INC position peaked at $5.47M in Q1 2021.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.